News filtered by category

A contract laboratory can receive a 483, submit an inadequate response, get a warning letter, and land on import alert over the course of months, and the sponsor that depends on its data may not be told at any point in that sequence.

FDA inspection readiness can no longer be treated as a short-term preparation exercise before an expected inspection. For pharmaceutical, biotechnology, and medical device organizations, maintaining continuous inspection readiness means building a quality system that produces evidence of compliance during everyday operations—not just when an inspection is approaching.

An effective corrective and preventive action (CAPA) program should do more than document that an issue was addressed. It should demonstrate that the root cause was identified, the appropriate corrective action was implemented, and the fix actually worked.